Eli Lilly's Retatrutide Cuts Weight 28.7% in Phase 3 Trial, Beating Current GLP-1 Benchmarks
Updated
Updated · PharmaVoice · May 18
Eli Lilly's Retatrutide Cuts Weight 28.7% in Phase 3 Trial, Beating Current GLP-1 Benchmarks
6 articles · Updated · PharmaVoice · May 18
A high-dose retatrutide arm cut body weight by 28.7%—about 71.2 pounds after 68 weeks—in Lilly’s phase 3 Triumph-4 study in obesity and knee osteoarthritis.
The triple-hormone drug targets GLP-1, GIP and glucagon, and the trial also reduced knee pain, with more than 1 in 8 patients reporting they were pain-free by the end.
Common GLP-1 stomach side effects still appeared, and excessive weight loss drove higher discontinuation among patients who entered with a BMI of 35 or lower.
Retatrutide’s result tops the roughly 15% to 20% weight loss seen in a late-stage study of Lilly’s tirzepatide, strengthening its case as a next-generation obesity treatment.
Lilly plans more 2026 readouts, including Triumph-1 in June and additional obesity, diabetes, sleep apnea and back-pain trials, as the GLP-1 market heads toward a projected $100 billion by 2030.
Could a new drug that prevents weight regain make today's blockbuster treatments obsolete before they even dominate the market?
Is the record-breaking weight loss from new drugs worth the risk of novel side effects and high discontinuation rates?
As drugs are found to rewire brain pleasure circuits, is the future of weight loss also the future of addiction treatment?
Retatrutide’s 28.7% Weight Loss Sets New Benchmark in Obesity and Type 2 Diabetes Care
Overview
Retatrutide, developed by Eli Lilly and Company, is a groundbreaking treatment for obesity and type 2 diabetes. As a first-in-class triple hormone receptor agonist, it activates the GIP, GLP-1, and GCG receptors, with especially high potency at the GIP receptor. In late-stage clinical trials, retatrutide delivered the most substantial weight loss seen so far, particularly highlighted in the pivotal TRIUMPH-4 trial for people with obesity and knee osteoarthritis. Its unique mechanism and impressive results mark a major advancement in metabolic health management, offering new hope for patients struggling with weight and related conditions.